About Aurobindo Pharma
Recent News Around Aurobindo Pharma
Aurobindo Pharma Q3 Fy2024 Key Points And Summary:
- In Q3 FY24, Aurobindo Pharma recorded revenue from operations of ₹7,352 Crore, marking a 14.7% year-on-year increase.
- The company’s US revenues (excluding Puerto Rico) amounted to US$ 451 Mn during the same period.
- EBITDA before Forex and Other income stood at ₹1,601 Crore, with an EBITDA margin of 21.8%.
- A notable net profit after minority interest of ₹936 Crore was achieved, reflecting a remarkable 90.6% year-on-year growth and 23.7% quarter-on-quarter growth.
- Basic & Diluted EPS reached ₹16.04, demonstrating a substantial year-on-year growth of 91.4%.
- The company’s net Capex amounted to US$ 103 million, including US$ 37 million allocated towards the PLI project.
- Aurobindo Pharma invested approximately US$ 230 million in the PLI project and US$ 305 million in the Biosimilar project by December 31st, 2023.
- In the US market, the company filed 7 ANDAs, received approval for 16 products, and launched 21 products.
- As of December 31st, 2023, the company’s net cash including investments totaled approximately US$ 49 million.
- Total R&D expenditure for the quarter amounted to ₹398 Crore.
Aurobindo Pharma Share Price Target 2024 To 2030
Aurobindo Pharma Share Price Target 2024
Month | Maximum Price (₹) | Minimum Price (₹) |
---|---|---|
April | ₹1,244.40 | ₹1,082.09 |
May | ₹1,226.01 | ₹1,066.10 |
June | ₹1,270.15 | ₹1,104.48 |
July | ₹1,257.45 | ₹1,093.43 |
August | ₹1,307.74 | ₹1,137.17 |
September | ₹1,360.05 | ₹1,182.66 |
October | ₹1,333.39 | ₹1,159.47 |
November | ₹1,373.39 | ₹1,194.25 |
December | ₹1,407.72 | ₹1,224.11 |
Aurobindo Pharma’s share price is expected to exhibit fluctuations in the coming months of 2024. In April, the maximum price is anticipated to reach ₹1,244.40, while the minimum price is expected to be around ₹1,082.09. As the months progress, the expected prices will vary, with gradual increases in the maximum price and corresponding rises in the minimum price. By December, the maximum price is forecasted to reach ₹1,407.72, reflecting a bullish trend, while the minimum price is expected to rise to ₹1,224.11, indicating a positive outlook for Aurobindo Pharma’s shares in the future.
Aurobindo Pharma Share Price Target 2025
when | Maximum Price | Minimum Price |
January 2025 | ₹1,435.88 | ₹1,104.52 |
February 2025 | ₹1,472.70 | ₹1,132.84 |
March 2025 | ₹1,530.13 | ₹1,177.02 |
April 2025 | ₹1,500.13 | ₹1,153.94 |
May 2025 | ₹1,456.43 | ₹1,120.33 |
June 2025 | ₹1,521.97 | ₹1,170.75 |
July 2025 | ₹1,492.13 | ₹1,147.79 |
August 2025 | ₹1,538.28 | ₹1,183.29 |
September 2025 | ₹1,592.12 | ₹1,224.71 |
October 2025 | ₹1,633.51 | ₹1,256.55 |
November 2025 | ₹1,674.35 | ₹1,287.96 |
December 2025 | ₹1,716.21 | ₹1,320.16 |
In 2025, Aurobindo Pharma’s share price is expected to demonstrate a positive trajectory, with both maximum and minimum prices showing an upward trend throughout the year. In January, the maximum price target is anticipated to be ₹1,435.88, while the minimum price is expected to reach ₹1,104.52. As the year progresses, both the maximum and minimum prices are projected to steadily increase. By December 2025, the maximum price target is forecasted to reach ₹1,716.21, indicating continued bullish momentum, while the minimum price is expected to rise to ₹1,320.16, reflecting a positive outlook for Aurobindo Pharma’s shares in the upcoming year.
Aurobindo Pharma Share Price Target 2026 To 2030
Year | Maximum Price (₹) | Minimum Price (₹) |
---|---|---|
2026 | ₹1,802.02 | ₹1,261.42 |
2027 | ₹1,982.22 | ₹1,387.56 |
2028 | ₹2,775.11 | ₹1,387.56 |
2029 | ₹2,402.70 | ₹1,201.35 |
2030 | ₹3,123.51 | ₹2,186.45 |
Aurobindo Pharma’s Financial Condition (Last 5 Years)
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
Sales + | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 27,895 |
Expenses + | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 22,778 |
Operating Profit | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,117 |
OPM % | 20% | 21% | 21% | 19% | 15% | 18% |
Other Income + | 70 | 166 | 3,195 | 152 | 291 | 532 |
Interest | 263 | 305 | 74 | 49 | 140 | 256 |
Depreciation | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,513 |
Profit before tax | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 3,880 |
Tax % | 24% | 24% | 27% | 22% | 26% | |
Net Profit + | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 2,768 |
EPS in Rs | 40.36 | 48.56 | 91.05 | 45.2 | 32.9 | 47.28 |
Dividend Payout % | 6% | 6% | 4% | 20% | 23% |
FAQS
Should one invest in Aurobindo Pharma?
Leave a Reply